Ness Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Ness Therapeutics General Information

Description

Operator of a biotechnology company intended to protect from all respiratory virus infections. The company aims to disrupt conventional methods such as vaccines and pathogen-targeted therapeutics by drawing inspiration from the innate immune system, enabling the healthcare industry to establish a virus-agnostic strategy to block transmission from infected individuals.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • MaRS Discovery District
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (415)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Eilean Therapeutics
Vertical(s)
Corporate Office
  • MaRS Discovery District
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ness Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 04-Mar-2024 Completed Clinical Trials - Phase 3
1. Seed Round 29-Apr-2021 Completed Startup
To view Ness Therapeutics’s complete valuation and funding history, request access »

Ness Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Ness Therapeutics’s complete cap table history, request access »

Ness Therapeutics Patents

Ness Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025517026-A Ptpn2 inhibitors Active 13-May-2022
WO-2023220572-A1 Ptpn2 inhibitors Inactive 13-May-2022
WO-2022261145-A1 Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes Inactive 10-Jun-2021 C07D285/10

Ness Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ness Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioGeneration Ventures Venture Capital Minority
OrbiMed Growth/Expansion Minority
i2020 Accelerator Accelerator/Incubator Minority
To view Ness Therapeutics’s complete investors history, request access »

Ness Therapeutics FAQs

  • When was Ness Therapeutics founded?

    Ness Therapeutics was founded in 2020.

  • Where is Ness Therapeutics headquartered?

    Ness Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Ness Therapeutics?

    Ness Therapeutics has 3 total employees.

  • What industry is Ness Therapeutics in?

    Ness Therapeutics’s primary industry is Biotechnology.

  • Is Ness Therapeutics a private or public company?

    Ness Therapeutics is a Private company.

  • What is Ness Therapeutics’s current revenue?

    The current revenue for Ness Therapeutics is .

  • How much funding has Ness Therapeutics raised over time?

    Ness Therapeutics has raised $7.5M.

  • Who are Ness Therapeutics’s investors?

    BioGeneration Ventures, OrbiMed, and i2020 Accelerator have invested in Ness Therapeutics.

  • When was Ness Therapeutics acquired?

    Ness Therapeutics was acquired on 04-Mar-2024.

  • Who acquired Ness Therapeutics?

    Ness Therapeutics was acquired by Eilean Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process